DE59310323D1 - Imidazol-derivate mit Biphenylsulfonylharnstoff- oder Biphenylsulfonylurethan-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung - Google Patents

Imidazol-derivate mit Biphenylsulfonylharnstoff- oder Biphenylsulfonylurethan-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung

Info

Publication number
DE59310323D1
DE59310323D1 DE59310323T DE59310323T DE59310323D1 DE 59310323 D1 DE59310323 D1 DE 59310323D1 DE 59310323 T DE59310323 T DE 59310323T DE 59310323 T DE59310323 T DE 59310323T DE 59310323 D1 DE59310323 D1 DE 59310323D1
Authority
DE
Germany
Prior art keywords
biphenylsulfonylurethane
biphenylsulfonylurea
preparation
side chain
imidazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59310323T
Other languages
German (de)
English (en)
Inventor
Dr Heitsch
Dr Henning
Dr Wagner
Dr Gerhards
Dr Becker
Prof Dr Schoelkens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to DE59310323T priority Critical patent/DE59310323D1/de
Application granted granted Critical
Publication of DE59310323D1 publication Critical patent/DE59310323D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
DE59310323T 1992-03-07 1993-03-02 Imidazol-derivate mit Biphenylsulfonylharnstoff- oder Biphenylsulfonylurethan-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung Expired - Lifetime DE59310323D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE59310323T DE59310323D1 (de) 1992-03-07 1993-03-02 Imidazol-derivate mit Biphenylsulfonylharnstoff- oder Biphenylsulfonylurethan-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07
DE59310323T DE59310323D1 (de) 1992-03-07 1993-03-02 Imidazol-derivate mit Biphenylsulfonylharnstoff- oder Biphenylsulfonylurethan-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung

Publications (1)

Publication Number Publication Date
DE59310323D1 true DE59310323D1 (de) 2003-02-13

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
DE59310323T Expired - Lifetime DE59310323D1 (de) 1992-03-07 1993-03-02 Imidazol-derivate mit Biphenylsulfonylharnstoff- oder Biphenylsulfonylurethan-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung

Country Status (25)

Country Link
US (1) US5604251A (US20070244113A1-20071018-C00087.png)
EP (1) EP0560177B1 (US20070244113A1-20071018-C00087.png)
JP (1) JP3542813B2 (US20070244113A1-20071018-C00087.png)
KR (1) KR930019637A (US20070244113A1-20071018-C00087.png)
CN (1) CN1036341C (US20070244113A1-20071018-C00087.png)
AT (1) ATE230732T1 (US20070244113A1-20071018-C00087.png)
AU (1) AU663565B2 (US20070244113A1-20071018-C00087.png)
BR (1) BR9300761A (US20070244113A1-20071018-C00087.png)
CA (1) CA2091135A1 (US20070244113A1-20071018-C00087.png)
CZ (1) CZ281983B6 (US20070244113A1-20071018-C00087.png)
DE (1) DE59310323D1 (US20070244113A1-20071018-C00087.png)
DK (1) DK0560177T3 (US20070244113A1-20071018-C00087.png)
ES (1) ES2187501T3 (US20070244113A1-20071018-C00087.png)
FI (1) FI930970A (US20070244113A1-20071018-C00087.png)
HU (1) HUT64041A (US20070244113A1-20071018-C00087.png)
IL (1) IL104971A0 (US20070244113A1-20071018-C00087.png)
MA (1) MA22814A1 (US20070244113A1-20071018-C00087.png)
NO (1) NO303632B1 (US20070244113A1-20071018-C00087.png)
NZ (1) NZ247059A (US20070244113A1-20071018-C00087.png)
PH (1) PH31466A (US20070244113A1-20071018-C00087.png)
PL (1) PL173023B1 (US20070244113A1-20071018-C00087.png)
RU (1) RU2116300C1 (US20070244113A1-20071018-C00087.png)
SK (1) SK279109B6 (US20070244113A1-20071018-C00087.png)
TW (1) TW215434B (US20070244113A1-20071018-C00087.png)
ZA (1) ZA931585B (US20070244113A1-20071018-C00087.png)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
CZ263098A3 (cs) 1996-02-20 1999-05-12 Bristol-Myers Squibb Company Způsoby přípravy bifenylisoxazolsulfonamidů
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
CA2274789A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU748334B2 (en) 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP2002540088A (ja) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ビフェニルイソキサゾール・スルホンアミド化合物の製造法
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
EP1631268A2 (en) * 2003-05-21 2006-03-08 Board Of Regents The University Of Texas System Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1685108B1 (en) * 2003-11-03 2008-07-23 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CA2544763A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
EP1699436A2 (en) * 2003-12-12 2006-09-13 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
US20060025463A1 (en) * 2004-03-22 2006-02-02 Michael Bristow Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
EP1737447A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
CA2572179A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US20090220507A1 (en) * 2005-07-22 2009-09-03 Sucharov Carmen C Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
US20090306373A1 (en) * 2005-12-20 2009-12-10 Gamber Gabriel G 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
AU2007281261B2 (en) 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
JP5587777B2 (ja) 2007-07-31 2014-09-10 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 線維症をモジュレートするマイクロrnaファミリー及びその使用
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
EP0599999A1 (en) * 1991-08-19 1994-06-08 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения

Also Published As

Publication number Publication date
IL104971A0 (en) 1993-07-08
ES2187501T3 (es) 2003-06-16
CZ281983B6 (cs) 1997-04-16
ATE230732T1 (de) 2003-01-15
FI930970A0 (fi) 1993-03-04
CA2091135A1 (en) 1993-09-08
FI930970A (fi) 1993-09-08
JPH069572A (ja) 1994-01-18
NO930817L (no) 1993-09-08
NZ247059A (en) 1995-03-28
AU3401193A (en) 1993-09-09
CZ381192A3 (en) 1993-12-15
MA22814A1 (fr) 1993-10-01
PL297955A1 (en) 1993-09-20
EP0560177B1 (de) 2003-01-08
EP0560177A1 (de) 1993-09-15
AU663565B2 (en) 1995-10-12
JP3542813B2 (ja) 2004-07-14
PH31466A (en) 1998-11-03
RU2116300C1 (ru) 1998-07-27
SK381192A3 (en) 1998-06-03
DK0560177T3 (da) 2003-04-14
KR930019637A (ko) 1993-10-18
PL173023B1 (pl) 1998-01-30
CN1036341C (zh) 1997-11-05
BR9300761A (pt) 1993-09-14
ZA931585B (en) 1993-09-27
US5604251A (en) 1997-02-18
CN1076192A (zh) 1993-09-15
TW215434B (US20070244113A1-20071018-C00087.png) 1993-11-01
HU9300618D0 (en) 1993-05-28
HUT64041A (en) 1993-11-29
NO303632B1 (no) 1998-08-10
SK279109B6 (sk) 1998-06-03
NO930817D0 (no) 1993-03-05

Similar Documents

Publication Publication Date Title
DE59310323D1 (de) Imidazol-derivate mit Biphenylsulfonylharnstoff- oder Biphenylsulfonylurethan-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung
RU93004577A (ru) Производные имидазола с боковой цепью бифенилсульфонилмочевины
DE59209292D1 (de) Azol-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59309902D1 (de) Azachinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung
DK0533058T3 (da) Imidazo-kondenserede iso- og heterocykler som angiotensin-II-antagonister
ATE156818T1 (de) Polyfluoralkylthiopoly(ethylimidazolium)- verbindungen, verfahren zu ihrer herstellung und ihre verwendung als biozide mittel
DE59209965D1 (de) Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2371012A1 (en) 4-(1h-pyrrol-1-yl) imidazoles
ATA20991A (de) Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
PT781126E (pt) Derivados de 2-amino-1,2,3,4-tetra-hidro naftalino activos no sistema cardiovascular
DE59309756D1 (de) 4-Iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung
ES2063562T3 (es) Uso de 5,6-dihidro-dibenz(b,e)acepina-6,11-dion-11-oximas en la elaboracion de sustancias antirretrovirales.
ATE90677T1 (de) Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
DE59306309D1 (de) Benzophenon-Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung
DE59200787D1 (de) 6-Thiono-5,6-dihydro-dibenz[b,e]azepin-11-on-11-oxime und ihre Verwendung als retrovirale Mittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition